SNIPER(ABL)-020

• UNSPSC Description:

  SNIPER(ABL)-020, conjugating Dasatinib (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein[1].

• Target Antigen:

  Bcr-Abl; SNIPERs

• Type:

  Reference compound

• Related Pathways:

  PROTAC;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/sniper-abl-020.html

• Purity:

  99.79

• Solubility:

  DMSO : 200 mg/mL (ultrasonic)

• Smiles:

  CC1=C(NC(C2=CN=C(NC3=CC(N4CCN(C(COCCOCCOCCNC([C@H](CC(C)C)NC([C@@H](O)[C@@H](CC5=CC=CC=C5)N)=O)=O)=O)CC4)=NC(C)=N3)S2)=O)C(Cl)=CC=C1

• Molecular Weight:

  923.52

• References & Citations:

  [1]Shibata N, et al. Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands. Cancer Sci. 2017 Aug;108(8):1657-1666.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, stored under nitrogen)

• Clinical Information:

  No Development Reported